Pharmaceuticals

G-CSF (Granulocyte Colony Stimulating Factors) Market Developments And Opportunities Across 2026–2030

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The G-CSF (Granulocyte Colony Stimulating Factors) Market Grow Between 2026 And 2030?

The g-csf (granulocyte colony stimulating factors) market has shown steady expansion in recent years. It is projected to grow from $9.48 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. Historically, this growth can be attributed to factors such as the limited availability of g-csf therapies, a rising prevalence of chemotherapy-induced neutropenia, an increasing oncology patient population, regulatory approvals for first-generation g-csf products, and the adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Several factors are expected to drive this growth during the forecast period, including the introduction of new g-csf products, the spread of biosimilars into developing markets, increased application of combination treatments, growing consumer preference for pre-filled syringe formulations, and enhanced funding for supportive care and neutropenia management initiatives. Key trends anticipated during this period encompass a surge in the need for g-csf biosimilars, wider acceptance of pre-filled syringes and injectable forms, an increase in combination therapies utilizing other growth factors, broadened application of g-csf in treating oncology and blood disorders, and heightened recognition of the importance of neutropenia management and supportive care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Major Factors Are Driving The G-CSF (Granulocyte Colony Stimulating Factors) Market Forward?

The increasing incidence of cancer is projected to stimulate the growth of the G-CSF (granulocyte colony stimulating factor) market moving forward. Cancer is defined as a disease characterized by the uncontrolled propagation and spread of abnormal cells, which can disrupt normal bodily functions and ultimately lead to death. The rise in cancer prevalence is influenced by factors such as aging populations, changes in lifestyle, and environmental exposures that elevate cancer risk. The G-CSF market supports this trend by providing growth factors that stimulate the production of white blood cells, thereby mitigating the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023, averaging 972 per day, which represents 8,605 more cases than in 2022. Therefore, the growing prevalence of cancer is a key driver for the expansion of the G-CSF (granulocyte colony stimulating factor) market.

How Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Categorized Across Its Segment Groups?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

What Trends Are Influencing The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Leading companies in the G-CSF (granulocyte colony stimulating factor) market are prioritizing technological advancements in hematopoietic therapies, particularly through dimeric fusion protein design, to boost neutrophil production and decrease immunogenicity in extended-release G-CSF treatments. Dimeric fusion protein design involves connecting two G-CSF molecules into a singular protein to prolong its half-life and enhance receptor activation without the need for PEGylation. For instance, in November 2023, Evive Biotech Inc., a biopharmaceutical company based in Singapore, secured U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa). This long-acting biosimilar G-CSF is approved for reducing the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, encourages neutrophil generation in the bone marrow, thus hastening the recovery of neutrophil counts. Its significant characteristics include prolonged dosing, adaptability with various chemotherapy regimens, and availability in a convenient prefilled syringe. The product is utilized for the prevention of chemotherapy-induced neutropenia, for stem cell mobilization, and as supportive care for immunocompromised patients, providing advantages such as fewer injections, better patient adherence, and improved overall patient results.

Which Firms Are Influencing Competition In The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Get The Full G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Geographic Region Dominates The G-CSF (Granulocyte Colony Stimulating Factors) Market?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized G-CSF (Granulocyte Colony Stimulating Factors) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795